These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 12754947)

  • 1. [Diagnostic value of gamma-glutamyltransferase in the metastatic disease of patients with renal cell carcinoma].
    Beltrán-Martínez RJ; Correa-Chacón AJ
    Gac Med Mex; 2003; 139(2):123-5. PubMed ID: 12754947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum gamma glutamyl-transferase is a sensitive but unspecific marker of metastatic renal cell carcinoma.
    Simic T; Dragicevic D; Savic-Radojevic A; Cimbaljevic S; Tulic C; Mimic-Oka J
    Int J Urol; 2007 Apr; 14(4):289-93. PubMed ID: 17470155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining.
    Weinbreck N; Marie B; Bressenot A; Montagne K; Joud A; Baumann C; Klein O; Vignaud JM
    Am J Surg Pathol; 2008 Jul; 32(7):1051-9. PubMed ID: 18496143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer.
    Goodale D; Phay C; Brown W; Gray-Statchuk L; Furlong P; Lock M; Chin-Yee I; Keeney M; Allan AL
    Cytometry B Clin Cytom; 2009 Mar; 76(2):107-17. PubMed ID: 18727054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Na,K-adenosine triphosphatase alpha1-subunit predicts survival of renal clear cell carcinoma.
    Seligson DB; Rajasekaran SA; Yu H; Liu X; Eeva M; Tze S; Ball W; Horvath S; deKernion JB; Rajasekaran AK
    J Urol; 2008 Jan; 179(1):338-45. PubMed ID: 18006011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin.
    Hock B; Schwarz M; Domke I; Grunert VP; Wuertemberger M; Schiemann U; Horster S; Limmer C; Stecker G; Soyka M
    Addiction; 2005 Oct; 100(10):1477-86. PubMed ID: 16185209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients.
    Antonelli A; Cozzoli A; Simeone C; Zani D; Zanotelli T; Portesi E; Cosciani Cunico S
    BJU Int; 2006 Mar; 97(3):505-8. PubMed ID: 16469016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
    Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
    Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
    J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
    Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
    Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
    Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
    Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
    Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
    Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.
    Shvarts O; Seligson D; Lam J; Shi T; Horvath S; Figlin R; Belldegrun A; Pantuck AJ
    J Urol; 2005 Mar; 173(3):725-8. PubMed ID: 15711252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
    Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma.
    Buchner A; Riesenberg R; Kotter I; Hofstetter A; Stief C; Oberneder R
    Cancer; 2006 Apr; 106(7):1514-20. PubMed ID: 16518813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The diagnostic validity of screening tests and laboratory markers in alcohol use disorders].
    Gül S; Akvardar Y; Taş G; Tuncel P
    Turk Psikiyatri Derg; 2005; 16(1):3-12. PubMed ID: 15793693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery.
    Ishimura T; Sakai I; Hara I; Eto H; Miyake H
    Int J Urol; 2004 May; 11(5):264-8. PubMed ID: 15147540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic models and algorithms in renal cell carcinoma.
    Lane BR; Kattan MW
    Urol Clin North Am; 2008 Nov; 35(4):613-25; vii. PubMed ID: 18992615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable.
    Vogl UM; Zehetgruber H; Dominkus M; Hejna M; Zielinski CC; Haitel A; Schmidinger M
    Br J Cancer; 2006 Sep; 95(6):691-8. PubMed ID: 16940978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.